Robert W. Baird has recently resumed Nurix Therapeutics Inc (NRIX) stock to Outperform rating, as announced on September 6, 2024, according to Finviz. Earlier, on July 31, 2024, Truist had initiated the stock to Buy, setting a price target of $36. Oppenheimer also resumed Outperform rating with a price target of $25. Additionally, Barclays initiated Overweight rating on March 9, 2023, with a target price of $20. Oppenheimer analysts, in their report published on February 28, 2023, also initiated Outperform rating and set a price target of $25 for Nurix Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Nurix Therapeutics Inc (NRIX) Stock Trading Recap
On Monday, Nurix Therapeutics Inc (NRIX) stock saw a decline, ending the day at $22.47 which represents a decrease of $-0.58 or -2.52% from the prior close of $23.05. The stock opened at $22.83 and touched a low of $22.14 during the day, reaching a high of $24. The volume of shares traded was 0.80 million exceeding the average volume of 0.71 million.
NRIX Stock Performance and Moving Averages
In recent trading, Nurix Therapeutics Inc (NRIX) stock price has shown some volatility, fluctuating -6.76% over the last five trades and -10.12% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 54.12%, and it has gained 7.46% in the previous three months. Currently, NRIX is trading at -7.60%, -2.54%, and 41.00% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, NRIX, a Healthcare sector stock, is trading -14.60% below its 52-week high but remains 432.46% above its 52-week low. The Average True Range (ATR) (14 days) of 1.32 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Nurix Therapeutics Inc’s Profitability and Valuation Ratios
Nurix Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -287.47% and a profit margin of -264.84%, with a gross margin of 54.12%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Nurix Therapeutics Inc’s market capitalization stands at $1.45 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 23.23, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 3.9, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.67% of Nurix Therapeutics Inc (NRIX)’s shares, while financial institutions hold 101.16%.
Notable insider trades include Ring Christine, Chief Legal Officer at Nurix Therapeutics Inc (NRIX), who sold 9050 shares on Sep 03 ’24, at $24.94 each, totaling $0.23 million. On Aug 26 ’24, Ring Christine, Chief Legal Officer, sold 9870 shares for $25.01 each, amounting to $0.25 million. Additionally, on Aug 26 ’24, van Houte Hans sold 20000 shares at $25.22 each, generating $0.50 million.
